Form 4: Pulmonx General Counsel Sells Over 10,000 Shares for Tax Obligations

Pulmonx Corporation's General Counsel, David Aaron Lehman, sold 10,457 shares of common stock on June 2, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• David Aaron Lehman, General Counsel of Pulmonx Corporation (LUNG), reported the sale of 10,457 shares of common stock.
• The transactions occurred on June 2, 2025, with shares sold at prices ranging from $3.13 to $3.14 per share.
• These sales were non-discretionary, executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) granted on various dates between June 1, 2021, and March 3, 2025.
• Following these transactions, Mr. Lehman's direct beneficial ownership of Pulmonx common stock decreased from 282,961 shares to 273,039 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, it's explicitly stated to be for tax withholding purposes related to RSU vesting, which is a common and often non-discretionary event, not typically signaling a lack of confidence.

Positives

• The sales were for tax withholding purposes, indicating a non-discretionary transaction rather than a sale based on a change in management's outlook on the company's prospects.

Negatives

• A reduction in insider ownership, even if for tax purposes, slightly decreases the alignment of management's financial interests with those of public shareholders.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Management Comments

• The reporting person sold shares to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs).

Industry Context

This filing is an insider transaction report specific to an individual executive's compensation and tax obligations, and does not directly reflect broader industry trends or competitive dynamics within the medical device or pulmonology sector.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but generally viewed as a routine event with minimal impact on shareholder confidence given the stated reason for the sale.
• Employees: No direct impact on employees, though it relates to executive compensation practices.

Key Dates

Recommendation

Keywords

Pulmonx, LUNG, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Corporate Governance, Executive Compensation